Ocular Delivery of Non-Peptide Somatostatin Agonists
SOMATOCOR PHARMACEUTICALS, INC. · Department of Health and Human Services
Phase I2004$134,820
DESCRIPTION (provided by applicant): We postulate that for future somatostatin therapies to treat posterior segment ocular diseases effectively, administration regimens must ensure that optimal drug levels are reached a…